Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,672 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome.
Aoki Y, Niihori T, Banjo T, Okamoto N, Mizuno S, Kurosawa K, Ogata T, Takada F, Yano M, Ando T, Hoshika T, Barnett C, Ohashi H, Kawame H, Hasegawa T, Okutani T, Nagashima T, Hasegawa S, Funayama R, Nagashima T, Nakayama K, Inoue S, Watanabe Y, Ogura T, Matsubara Y. Aoki Y, et al. Among authors: ando t. Am J Hum Genet. 2013 Jul 11;93(1):173-80. doi: 10.1016/j.ajhg.2013.05.021. Epub 2013 Jun 20. Am J Hum Genet. 2013. PMID: 23791108 Free PMC article.
Association between cerebrospinal fluid parameters and developmental and neurological status in glucose transporter 1 deficiency syndrome.
Nabatame S, Tanigawa J, Tominaga K, Kagitani-Shimono K, Yanagihara K, Imai K, Ando T, Tsuyusaki Y, Araya N, Matsufuji M, Natsume J, Yuge K, Bratkovic D, Arai H, Okinaga T, Matsushige T, Azuma Y, Ishihara N, Miyatake S, Kato M, Matsumoto N, Okamoto N, Takahashi S, Hattori S, Ozono K. Nabatame S, et al. Among authors: ando t. J Neurol Sci. 2023 Apr 15;447:120597. doi: 10.1016/j.jns.2023.120597. Epub 2023 Mar 2. J Neurol Sci. 2023. PMID: 36965413 Free article.
Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in Japan.
Hirata K, Hamamoto Y, Shoji H, Hara H, Kondoh C, Yasui H, Kajiwara T, Baba E, Ando T, Sugimoto N, Kawakami H, Katsuya H, Nagase M, Yamamoto Y, Yoshimura K, Ando M, Imamura CK, Yamazaki K, Hironaka S, Muro K. Hirata K, et al. Among authors: ando t. EClinicalMedicine. 2026 Jan 29;92:103768. doi: 10.1016/j.eclinm.2026.103768. eCollection 2026 Feb. EClinicalMedicine. 2026. PMID: 41660367 Free PMC article.
WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD).
Shimozaki K, Hirata K, Hayashi H, Sato Y, Komatsu Y, Taniguchi S, Takahashi N, Yamaguchi K, Furuta M, Kawakami T, Narita Y, Ando T, Makiyama A, Mitani S, Ogata T, Takegawa N, Okamoto W, Nishina T, Komoda M, Hosokawa A, Boku N, Kawakami H, Yamazaki K, Muro K. Shimozaki K, et al. Among authors: ando t. ESMO Gastrointest Oncol. 2025 Jun 9;9:100189. doi: 10.1016/j.esmogo.2025.100189. eCollection 2025 Sep. ESMO Gastrointest Oncol. 2025. PMID: 41647978 Free PMC article.
3,672 results